IL91778A - A method for reducing the heterogeneity of monoclonal antibodies - Google Patents

A method for reducing the heterogeneity of monoclonal antibodies

Info

Publication number
IL91778A
IL91778A IL9177889A IL9177889A IL91778A IL 91778 A IL91778 A IL 91778A IL 9177889 A IL9177889 A IL 9177889A IL 9177889 A IL9177889 A IL 9177889A IL 91778 A IL91778 A IL 91778A
Authority
IL
Israel
Prior art keywords
antibodies
incubation
heterogeneity
culture
hours
Prior art date
Application number
IL9177889A
Other languages
English (en)
Hebrew (he)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/364,056 external-priority patent/US5126250A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL91778A publication Critical patent/IL91778A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL9177889A 1988-09-28 1989-09-26 A method for reducing the heterogeneity of monoclonal antibodies IL91778A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25078888A 1988-09-28 1988-09-28
US25078688A 1988-09-28 1988-09-28
US25078788A 1988-09-28 1988-09-28
US07/364,056 US5126250A (en) 1988-09-28 1989-06-09 Method for the reduction of heterogeneity of monoclonal antibodies
CA000613379A CA1332367C (en) 1988-09-28 1989-09-26 Method for the reduction of heterogeneity of monoclonal antibodies

Publications (1)

Publication Number Publication Date
IL91778A true IL91778A (en) 1994-10-07

Family

ID=27508376

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9177889A IL91778A (en) 1988-09-28 1989-09-26 A method for reducing the heterogeneity of monoclonal antibodies

Country Status (17)

Country Link
EP (1) EP0361902B1 (de)
JP (1) JP2925181B2 (de)
CN (1) CN1041392A (de)
AR (1) AR242986A1 (de)
AT (1) ATE101876T1 (de)
AU (1) AU615576B2 (de)
BG (1) BG60017B2 (de)
CA (1) CA1332367C (de)
DE (1) DE68913251T2 (de)
DK (1) DK475389A (de)
ES (1) ES2049332T3 (de)
IE (1) IE63562B1 (de)
IL (1) IL91778A (de)
MX (1) MX170441B (de)
NZ (1) NZ230786A (de)
PL (1) PL162260B1 (de)
RO (1) RO105652B1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP1878747A1 (de) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-hergestellte Antikörper
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (de) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modifizierte antikörperkonstantregion
EP2275443B1 (de) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen bindendes molekül, das dazu in der lage ist, wiederholt zwei oder mehr antigenmoleküle zu binden
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
MY163081A (en) * 2010-12-28 2017-08-15 Chugai Pharmaceutical Co Ltd Animal cell culturing method
WO2013164694A1 (en) 2012-04-30 2013-11-07 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
PL2970512T3 (pl) * 2013-03-12 2019-03-29 Biocon Limited Immunomodulujące białka fuzyjne i sposoby ich otrzymywania
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
TWI873632B (zh) 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
PL3299810T3 (pl) 2015-05-19 2021-12-13 National Center Of Neurology And Psychiatry Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm)
PT3500586T (pt) * 2016-10-17 2021-06-17 Enzene Biosciences Ltd Processo contínuo para reduzir a heterogeneidade da proteína terapêutica
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
TWI872251B (zh) 2020-05-29 2025-02-11 日商中外製藥股份有限公司 含有抗體製劑

Also Published As

Publication number Publication date
BG60017B2 (bg) 1993-06-30
AU615576B2 (en) 1991-10-03
EP0361902A2 (de) 1990-04-04
AR242986A1 (es) 1993-06-30
DE68913251D1 (de) 1994-03-31
IE893094L (en) 1990-03-28
EP0361902B1 (de) 1994-02-23
CN1041392A (zh) 1990-04-18
ATE101876T1 (de) 1994-03-15
DK475389A (da) 1990-03-29
DK475389D0 (da) 1989-09-27
AU4234389A (en) 1990-04-05
EP0361902A3 (en) 1990-08-16
JPH02163096A (ja) 1990-06-22
MX170441B (es) 1993-08-23
JP2925181B2 (ja) 1999-07-28
RO105652B1 (ro) 1992-11-30
CA1332367C (en) 1994-10-11
ES2049332T3 (es) 1994-04-16
NZ230786A (en) 1991-11-26
DE68913251T2 (de) 1994-06-23
PL162260B1 (pl) 1993-09-30
IE63562B1 (en) 1995-05-17

Similar Documents

Publication Publication Date Title
US5126250A (en) Method for the reduction of heterogeneity of monoclonal antibodies
EP0361902B1 (de) Verfahren zur Verringerung der Heterogenität von monoklonalen Antikörpern
US4954437A (en) Cell encoding recombinant human erythropoietin
KR0157983B1 (ko) 아미드화 효소 발현계
CA2280791A1 (en) Immunological detection of prions
JPH06113832A (ja) ジゴキシンに対し高い親和性を有するモノクローナル抗体を産生するハイブリッドセルライン及びその製造法
WO1986004336A1 (en) Monoclonal antibodies against core proteins of lymphadenopathy-associated-viruses
JPH0638743A (ja) 抗プロテインｃモノクローナル抗体およびそれを産生するハイブリドーマ
AU712759B2 (en) TNF-alpha converting enzyme
EP0162034B1 (de) Verfahren zur Isolierung von monoklonalen Antikörpern aus Hybridomas-Kulturen
EP0169239A1 (de) Cdna-klone von menschlichem erythropoietin
US5236836A (en) Autoantibodies which enhance the rate of a chemical reaction
EP0300459A2 (de) Menschlicher pankreatischer sekretorischer Trypsininhibitor
EP0132021B1 (de) TGF-Polypeptide, davon derivierte antigene Oligopeptide, davon erhaltene Antikörper
EP0519728A2 (de) Anti-TCF-II monoklonale Antikörper und ihre Verwendung zur Bestimmung von TCF-II
JPH10226700A (ja) Ｍｉａの検出のためのイムノアッセイ
EP0445750A1 (de) Monoklonaler Antikörper gegen mit Krebs assoziierte humane Galactosyltransferase
Cone Non-MHC-restricted T cell antigen-binding proteins
EP0559428B1 (de) Neue Polypeptide, deren kodierende DNS
Wunderlich et al. Use of recombinant fusion proteins for generation and rapid characterization of monoclonal antibodies: Application to the Kunitz domain of human β amyloid precursor protein
JP3865364B2 (ja) コンドロイチナーゼ画分
JP4361578B2 (ja) コンドロイチン硫酸リアーゼｉｉに対するモノクローナル抗体
EP0336441B1 (de) Anti-CPBII-monoklonaler Antikörper
WO2000009739A1 (en) Monoclonal antibody against canine trypsin
EP0420151A1 (de) Antirhodopsiner monoklonaler Antikörper and seine Verwendung

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees